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Abstract
We report a 14-year-old girl with juvenile dermatomyositis (JDM) complicated by severe inflammatory calcinosis
successfully treated with thalidomide. She was diagnosed as JDM when she was 4 years old after a few months of
increasing lethargy, muscle pain, muscle weakness, and rash. During three months, clinical manifestations and
abnormal laboratory findings were effectively treated with oral prednisolone. However, calcinosis was recognized
18 months after disease onset. Generalized calcinosis rapidly progressed with high fever, multiple skin/subcuta-
neous inflammatory lesions, and increased level of CRP. Fifty mg/day (1.3 mg/kg day) of oral thalidomide was
given for the first four weeks, and then the dose was increased to 75 mg/day. Clinical manifestations subsided, and
inflammatory markers had clearly improved. Frequent high fever and local severe pain with calcinosis were sup-
pressed. The levels of FDP-E, IgG, and tryglyceride, which were all elevated before the thalidomide treatment, were
gradually returned to the normal range. Over the 18 months of observation up to the present, she has had no
inflammatory calcinosis, or needed any hospitalization, although established calcium deposits still remain. Her con-
dition became painless, less extensive and less inflammatory with the CRP level below 3.08 mg/dL. Recent exami-
nation by whole-body 18F-FDG-PET-CT over the 15 months of thalidomide treatment demonstrated fewer hot
spots around the subcutaneous calcified lesions.
Background
Juvenile dermatomyositis (JDM) is a systemic connective
tissue disease characterized by typical skin rash and
chronic muscle inflammation of uncertain etiology [1].
Classic JDM presents with an insidious progression of
malaise, easy fatigue, muscle weakness, fever, and rash
that may predate diagnosis by three to six months. Cal-
cinosis is one of the severe complications of JDM, and
despite recent progress in the treatment of this disorder,
it still occurs in up to 40% of patients [2,3]. The onset
of calcinosis usually occurs one to three years after that
of the illness.
Our understanding of the pathogenesis of calcinosis is
still very limited. However, it has begun to come into
focus through the following recent findings. The calci-
nosis itself is associated with inflammation. It has been
reported that macrophages and proinflammatory
cytokines, such as IL-6, IL-1, and TNF-alpha, were pre-
sent in the white, calcium-rich fluid (calcium milk) col-
lected from a patient [4]. Moreover, calcinosis has been
more frequently associated with TNF-alpha-308A pro-
moter polymorphism, which is associated with increased
TNF- alpha production by peripheral blood mononuc-
lear cells [5].
The deposition of calcium, mostly in the skin, around
the joints, and in the intermuscular fascial planes, may
cause more long-term disability than the myositis itself.
The relatively low incidence of calcinosis observed in
recently reported case series suggests that earlier diag-
nosis and more aggressive treatment such as corticoster-
oid and immunosuppressant therapy are required [6].
However, once established, the disease is still difficult to
treat.
Recently, the effectiveness of the monoclonal antibody
to TNF-alpha, infliximab, in the treatment of refractory
juvenile dermatomyositis with calcinosis has been
reported [7]. In that study, calcinosis was still present in
all five patients who received infliximab, but, notably, it
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widespread.
Thalidomide has been accepted as an immunomodula-
tory drug in refractory pediatric autoimmune diseases
such as Behcet’s disease and systemic onset juvenile
idiopathic arthritis [8,9]. It has been demonstrated that
thalidomide selectively inhibits the TNF-alpha and IL-6
mRNA expression in human peripheral blood mononuc-
lear cells [10]. The inhibitory effect of thalidomide on
monocyte TNF-alpha is thought to be the main
mechanism of its action as an anti-inflammatory agent
[11].
We report a case of severe calcinosis in a 14-year-old
girl who was treated with thalidomide, a treatment
encouraged by the partial effectiveness of etanercept, a
soluble TNF receptor fusion protein.
Case presentation
The patient was a girl of 14 years of age, in whom JDM
had been diagnosed in January 1998, when, at 4 years of
age, she had been experiencing increasing lethargy, mus-
cle pain, muscle weakness, and rash for a few months.
Calcinosis had been recognized 18 months after the
diagnosis was made (Fig. 1). For 3 months, clinical man-
ifestations and abnormal laboratory findings were effec-
tively treated with oral prednisolone. Her muscle
weakness and elevated muscle-derived enzymes were
normalized with this treatment, and the myositis was
stable after that. However, generalized calcinosis pro-
gressed rapidly with high fever, multiple skin and subcu-
taneous inflammatory lesions, and an increased level of
CRP. Examination of the subcutaneous calcium milk
revealed markedly elevated levels of IL-6, TNF-alpha,
and IL-1beta by ELISA (Fig 2). Methylprednisolone
pulses, cyclophosphamide, cyclosporine, azathioprine,
probenecid and magnesium hydroxide and aluminum
hydroxide were administered, but these treatments
failed, resulting in repeated rupture, drainage and resec-
tion at calcinosis sites (Fig 3). “Inflammatory calcinosis”
events, defined as subcutaneous inflammation caused by
calcification with one or more of the following, (1) pain
(VAS>50 mm), (2) fever (>38.0°C, and (3) an elevated
level of CRP (>5 mg/dL), were not suppressed by the
conventional treatments at all. As shown in Fig. 4,
fusion imaging systems combining 18F-FDG PET
(Fluorodeoxyglucose-Positron Emission Tomography)
and CT visualized anatomical location of the hot spot
lesions of inflammatory calcinosis. Pathological evalua-
tion of this inflammatory calcinosis revealed calcium
plaques with fibrinoid vasculitis, inflammatory cell infil-
tration, hemorrhage and degeneration of adipose cells.
(Fig. 5)
Infliximab, the monoclonal antibody to TNF-alpha,
was administered in 2003, when the patient was 9 years
Figure 1 X-ray findings of extremities and pelvis.a .C a l c i u m
deposit around right knee in April 2001, 3 years and 3 months after
JDM onset. b. Subcutaneous calcium nodule over right elbow in
January 2003, 5 years after JDM onset. c. Tumoral calcinosis in the
buttocks in September 2003, 5 years and 8 months after JDM onset.
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replaced with etanercept. Being encouraged by the par-
tial effectiveness of subcutaneous injection of 25 mg (0.8
mg/kg) of etanercept twice a week, her high fevers
became less frequent. However, surgical approaches to
the removal of the calcium deposits were still required
because of inflammatory calcinosis with severe pain,
rupture, or both at the calcinosis sites.
Etanercept treatment was replaced with thalidomide
treatment in 2006 at the age of 12 after receiving
approval from the ethical committee and informed con-
sent from the patient and her parents. Fifty mg/day (1.3
mg/kg day) of oral thalidomide (Sauramide®, Penn
Pharmaceuticals, Tredegar, UK) was given for the first
four weeks, and then the dose was increased to 75 mg/
day. Clinical manifestations subsided, and inflammatory
markers had clearly improved (Table 1). Frequent high
fever and local severe pain with calcinosis were sup-
pressed. The levels of FDP-E, IgG, and tryglyceride,
which were all elevated before the thalidomide treat-
ment, were gradually returned to the normal range.
Over the 18 months of observation up to the present,
she has had no inflammatory calcinosis, or needed any
hospitalization, although established calcium deposits
still remain. Her condition became painless, less exten-
sive and less inflammatory with the CRP level below
Figure 2 Calcium milk drained with small amounts of calcium deposits from buttock (top). Characteristics of proinflammatory cytokines in
serum and calcium milk. (bottom). Examination of subcutaneous calcium milk revealed highly elevated levels of IL-6, TNF-a, and IL-1b.
Figure 3 Clinical course of the patient and “inflammatory calcinosis” defined as subcutaneous inflammation caused by calcification
with one or more of: (1) pain (VAS>50 mm), (2) fever (>38.0°), and (3) elevated level of CRP (>5 mg/dL). K: knee, E: elbow, T: thigh, B:
buttock, W: wrist, mPSL: methyl prednisolone; IVCY:intravenous cyclophosphamide pulse.
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FDG-PET-CT over the 15 months of thalidomide treat-
ment demonstrated fewer hot spots around the subcuta-
neous calcified lesions.
Discussion
Treatment with thalidomide produced a sustained major
clinical improvement in a case of JDM with inflamma-
tory calcinosis refractory to the conventional corticoster-
oids and immunosuppressants and even to etanercept.
The mechanism of the inflammatory calcinosis of JDM
is still unclear. Pachman et al. speculated that calcification
occurring at sites where it is undesirable, as opposed to
physiologic calcification, is usually designated as “patholo-
gic” or, when associated with cell death, as “dystrophic” in
nature [12]. Scientifically, at least, as Table 1 shows, it has
been shown that inflammation accompanied by calcinosis
is characterized by multiple proinflammatory cytokinemia
including TNF-alpha, IL-6, and IL-1beta. The level of IL-
10 in the calcium milk was also elevated. IL-10 is a cyto-
kine with potent anti-inflammatory properties, which
represses the expression of inflammatory cytokines such
as TNF-alpha, IL-6 and IL-1 by activated macrophages.
This finding may indicate that in parallel with the
Figure 4 Findings of 18 FDG-PET/CT showing “inflammatory calcinosis"in August 2006. Subcutaneous and intramuscular calcification were
recognized as in conventional plain CT. Hot spots (white arrow) along with intramuscular calcification indicate inflammation. Even the small
lesion of inflammation around a right digit (yellow arrow) can be seen clearly.
Figure 5 Light microscopy of calcium deposits with soft tissue obtained in the left thigh during surgery. Bordered with calcium plaques
(arrow), fibrinoid vasculitis was observed with hemorrhage and degeneration of adipose cells. (H&E stain, 20×).
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injury pathways caused by TNF-alpha, IL-6 and IL-1, there
is simultaneous activation of pathways for the counter-reg-
ulatory and the protective mechanisms that would balance
and limit the ongoing inflammatory/immune responses.
The effect of infliximab in refractory calcinosis with
juvenile dermatomyositis was reported previously [7].
The anti-TNF-alpha biologics such as infliximab and
etanercept are designed specifically to target TNF-alpha.
Unlike the mechanism of action of the biologics, thali-
domide has complex immunomodulatory and anti-
inflammatory properties. It has been shown to downre-
gulate the production of TNF-alpha and other proin-
flammatory cytokines, to inhibit the transcription factor
nuclear factor kappa B (NF kappaB), and to downregu-
late cyclooxygenase 2 [13,14]. This might explain why
thalidomide was more effective in the present case than
etanercept. The calcified deposits contained the bone
proteins osteopontin, osteonectin, and sialoprotein.
Hydroxyapatite was the only mineral detected, but the
tissue was distinct from bone, with an extremely high
mineral content and an irregular distribution of minerals
[12]. The same authors also reported that calcifications
from JDM patients contained more osteonectin than is
usually found in human bone. In vitro studies indicate
that osteonectin can bind collagen and regulate angio-
genesis, metalloproteinase expression, cell proliferation,
and cell-matrix interactions [15].
Thalidomide is not only an immunomodulatory drug
but also has anti-angiogenic effects [16]. It has been
reported, for example, in myeloma, to suppress angio-
genic factors such as vascular endothelial growth factor
(VEGF), and inflammatory g e n e ss u c ha sT N F - a l p h a
and IL-6 [17,18]. The anti-angiogenic effect may be a
part of the thalidomide mechanism that reverses inflam-
matory calcinosis.
The pathological specimen showed fibrinoid vasculitis
surrounding calcinosis. It is hard to explain whether the
inflammatory calcinosis is due to muscle vasculitis because
there was no muscle vasculitis where no calcinosis was
present. Muscle vasculitis arising from JDM should be
symmetrical. We prefer to surmise that fibrinoid vasculitis
was followed by the calcinosis universalis itself. Besides, no
report of a direct relationship between vasculitis and calci-
nosis universalis has appeared in the literature.
The findings of 18F-FDG-PET-CT after thalidomide
treatment included fewer hot spots showing local
inflammation around subcutaneous calcified lesions.
This suggested that the subcutaneous pooling of calcium
milk may be the cause of proinflammatory cytokinemia
and subsequent “inflammatory calcinosis” in JDM, and
the suppression of NF kappaB activation by thalidomide
is likely to be beneficial for inhibiting the systemic
spread of inflammation.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor in Chief of this journal.
Table 1 Laboratory findings of the patient.
2001 2006
During inflammatory
calcinosis
Before thalidomide
(inacitive phase)
3 months 12 months
WBC (μL) 27,300 7,100 6,400 5,200
Hb (g/dL) 11.6 11.3 9.5 12.7
Platelets (×10
4/μL) 24.7 24.6 35.7 35.7
ESR (mm/h) 27 17 3 4
FDP-E (ng/mL) 225 237 95 85
AST (U/L) 20
ALT (U/L) 7
LDH (U/L) 271
CRP (mg/dL) 21.0 0.2 0.1 0.4
Triglycerides (mg/dL) nd 251 74 93
Total cholesterol (mg/dL) nd 121 145 156
IgG (mg/dL) nd 2,056 813 916
The levels of FDP-E, IgG, and triglycerides were all elevated before thalidomide gradually reduced them to the normal range.
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